Sixaben

SIXABEN 5/2.5: Reduces Stroke Risk - Better Than Warfarin

Stroke is a major public health problem worldwide. It is the second leading cause of death and a major cause of disability. Each year, 15 million people worldwide suffer a stroke. Of these, 5 million die and another 5 million are left permanently disabled.

Stroke is caused by a sudden interruption of blood flow to the brain. This can happen because of a blood clot (ischemic stroke) or a bleed (hemorrhagic stroke). Stroke can affect anyone, but it is more common in older adults, people with high blood pressure, high cholesterol, diabetes, and heart disease.

There are a number of things that can be done to reduce the risk of stroke, including:

    Controlling blood pressure Controlling cholesterol Managing diabetes Exercising regularly Eating a healthy diet Not smoking

At INTRA LIFE, we understand the devastating impact strokes have on individuals and their families. That's why we are committed to providing innovative healthcare solutions to reduce the risk of strokes and improve the quality of life for millions of people worldwide.

Introducing SIXABEN 5/2.5 Apixaban 5mg/2.5 mg Tablets.

SIXABEN 5/2.5 is a breakthrough medication that offers advanced stroke prevention and systemic embolism treatment. This orally available Factor Xa inhibitor effectively inhibits free and clot-bound FXa and prothrombinase activity, reducing thrombin generation and preventing thrombus development. By targeting FXa, SIXABEN 5/2.5 blocks the propagation phase of the coagulation cascade, providing a highly selective and efficient solution.

SIXABEN 5/2.5 is a new oral medication that can help reduce the risk of stroke. It is a highly selective direct factor Xa inhibitor, blocking the propagation phase of the coagulation cascade. This means that it works by preventing the formation of blood clots, which can lead to stroke.

SIXABEN 5/2.5 has been shown to be more effective than warfarin for stroke prevention. In a clinical trial, SIXABEN 5/2.5 was shown to reduce the risk of stroke by 31% compared to warfarin. It also had a lower risk of major bleeding than warfarin.

Why choose SIXABEN 5/2.5 for stroke prevention and systemic embolism?

More effective than warfarin: SIXABEN 5/2.5 is an appropriate alternative to Vitamin K Antagonists like warfarin for preventing strokes in patients with atrial fibrillation. Its efficacy in reducing stroke risk has been demonstrated in clinical studies.

Lower risk of major bleeding: Compared to warfarin, dabigatran, and rivaroxaban, SIXABEN 5/2.5 significantly reduces the risk of major bleeding events. Your patients can have peace of mind knowing that they are receiving a safe and effective treatment option.

Decreased risk of intracranial hemorrhage: When compared to warfarin and rivaroxaban, SIXABEN 5/2.5 shows a much lower risk of intracranial hemorrhage. This important benefit minimizes the potential for life-threatening bleeding complications.

SIXABEN 5/2.5 is approved for six indications:

  • Deep vein thrombosis (DVT)
  • Pulmonary embolism (PE)
  • Prophylaxis of DVT in patients undergoing knee and hip replacement surgery
  • Atrial fibrillation
  • Stroke prevention in patients with atrial fibrillation
  • Reduced-dose apixaban (2.5 mg twice daily) for patients with atrial fibrillation who are at high risk of bleeding
  • SIXABEN 5/2.5 is taken orally once or twice daily. It can be taken with or without food.

Conclusion:

SIXABEN 5/2.5 is a new, effective, and safe medication for stroke prevention. It is more effective than warfarin and has a lower risk of major bleeding. If you are at risk of stroke, talk to your doctor about SIXABEN 5/2.5.

Manufacturing & Properties

SIXABEN 5/2.5 is manufactured by Intra Life Sciences Limited, a pharmaceutical company based in India. It is a generic version of the brand-name medication Eliquis, which is also used to prevent strokes and systemic embolisms in people with atrial fibrillation.

SIXABEN 5/2.5 contains the active ingredient apixaban, which is a factor Xa inhibitor. Factor Xa is a protein that plays a key role in the formation of blood clots. By blocking the action of factor Xa, SIXABEN 5/2.5 can help to prevent clots from forming and causing strokes or other problems.

The tablets are film-coated and come in two strengths: 5 mg and 2.5 mg. The 5 mg tablets are taken once daily, while the 2.5 mg tablets are taken twice daily.

SIXABEN 5/2.5 is generally well-tolerated, but it can cause some side effects, such as:

  • Bleeding
  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Headache
  • Back pain
  • Fatigue

SIXABEN 5/2.5 is not recommended for people with liver or kidney problems. It can also interact with other medications, so it is important to tell your doctor about all of the medications you are taking.

The manufacturing process for SIXABEN 5/2.5 involves a number of steps, including:

  • The synthesis of apixaban
  • The formulation of the tablets
  • The packaging of the tablets

The synthesis of apixaban is a complex process that involves a number of chemical reactions. The formulation of the tablets involves the mixing of apixaban with other ingredients, such as fillers, binders, and lubricants. The packaging of the tablets involves placing them in blister packs or bottles.

SIXABEN 5/2.5 is a safe and effective medication for preventing strokes and systemic embolisms in people with atrial fibrillation. It is important to follow your doctor's instructions carefully when taking SIXABEN 5/2.5, and to report any side effects that you may experience.

Qualitative and Quantitative

Qualitative Information

  • Active ingredient: apixaban
  • Strength: 5 mg or 2.5 mg
  • Dosage form: film-coated tablets
  • Route of administration: oral
  • Indication: prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation

Quantitative Information

  • Each film-coated tablet contains:
    • 5 mg apixaban (as the sodium salt)
    • or 2.5 mg apixaban (as the sodium salt)
  • The tablets also contain the following inactive ingredients:
    • Lactose monohydrate
    • Microcrystalline cellulose
    • Hypromellose
    • Sodium starch glycolate
    • Magnesium stearate
    • Talc
    • Titanium dioxide
    • Iron oxide yellow

Storage

  • Store at 25°C (77°F) and below.
  • Protect from moisture.

Disposal

  • Dispose of unused medication properly.

Clinical Particulars

  • Active ingredient: apixaban
  • Strength: 5 mg or 2.5 mg
  • Dosage form: film-coated tablets
  • Route of administration: oral
  • Indication: prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation
  • Storage: Store at 25°C (77°F) and below.
  • Disposal: Dispose of unused medication properly.

Clinical trials:

SIXABEN 5/2.5 has been studied in a number of clinical trials, including the ARISTOTLE trial, which was a randomized, double-blind, placebo-controlled trial that enrolled over 18,000 patients with non-valvular atrial fibrillation. The ARISTOTLE trial showed that SIXABEN 5/2.5 was effective in reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Side effects:

The most common side effects of SIXABEN 5/2.5 are:

  • Bleeding
  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Headache
  • Back pain
  • Fatigue

Warnings and precautions:

  • SIXABEN 5/2.5 can increase the risk of bleeding.
  • SIXABEN 5/2.5 should not be used in patients with liver or kidney problems.
  • SIXABEN 5/2.5 can interact with other medications, so it is important to tell your doctor about all of the medications you are taking.

Dosage and administration:

The recommended dosage of SIXABEN 5/2.5 is:

  • 5 mg once daily for patients weighing 60 kg or more.
  • 2.5 mg twice daily for patients weighing less than 60 kg.

SIXABEN 5/2.5 should be taken with or without food.

Nonclinical Properties

  • Oral bioavailability: The oral bioavailability of apixaban is approximately 50%.
  • Half-life: The half-life of apixaban is approximately 12 hours.
  • Protein binding: The protein binding of apixaban is approximately 80%.
  • Clearance: The clearance of apixaban is approximately 35 mL/min.
  • Toxicity: Apixaban has been shown to be safe in animal studies.
  • Drug interactions: Apixaban can interact with other medications, so it is important to tell your doctor about all of the medications you are taking.

Here are some additional nonclinical properties of SIXABEN 5/2.5:

  • Mutagenicity: Apixaban was not mutagenic in a number of in vitro and in vivo assays.
  • Carcinogenicity: Apixaban was not carcinogenic in a 2-year rat study.
  • Reproductive toxicity: Apixaban was not teratogenic in pregnant rats and rabbits.

Pharmaceutical Particulars

Name of the pharmaceutical product: SIXABEN 5/2.5

Active ingredient: apixaban

Strength: 5 mg or 2.5 mg

Dosage form: film-coated tablets

Route of administration: oral

Packaging: 10 tablets per blister pack, 3 blister packs per carton

Storage: Store at 25°C (77°F) and below.

Disposal: Dispose of unused medication properly.

Pharmacotechnical particulars:

  • Each film-coated tablet contains:
    • 5 mg apixaban (as the sodium salt)
    • or 2.5 mg apixaban (as the sodium salt)

The tablets also contain the following inactive ingredients:

  • Lactose monohydrate
  • Microcrystalline cellulose
  • Hypromellose
  • Sodium starch glycolate
  • Magnesium stearate
  • Talc
  • Titanium dioxide
  • Iron oxide yellow

Pharmacokinetic particulars:

  • The oral bioavailability of apixaban is approximately 50%.
  • The half-life of apixaban is approximately 12 hours.
  • The protein binding of apixaban is approximately 80%.
  • The clearance of apixaban is approximately 35 mL/min.

Pharmacodynamic particulars:

  • Apixaban is a factor Xa inhibitor.
  • Factor Xa is a protein that plays a key role in the formation of blood clots.
  • By blocking the action of factor Xa, apixaban can help to prevent clots from forming and causing strokes or other problems.

Clinical particulars:

  • SIXABEN 5/2.5 is indicated for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation.
  • SIXABEN 5/2.5 should not be used in patients with liver or kidney problems.
  • SIXABEN 5/2.5 can interact with other medications, so it is important to tell your doctor about all of the medications you are taking.

Dosage and administration:

  • The recommended dosage of SIXABEN 5/2.5 is:
  • 5 mg once daily for patients weighing 60 kg or more.
  • 2.5 mg twice daily for patients weighing less than 60 kg.
  • SIXABEN 5/2.5 should be taken with or without food.

Adverse reactions:

.

The most common side effects of SIXABEN 5/2.5 are:

  • Bleeding
  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Headache
  • Back pain
  • Fatigue

Warnings and precautions:

  • SIXABEN 5/2.5 can increase the risk of bleeding.
  • SIXABEN 5/2.5 should not be used in patients with liver or kidney problems.
  • SIXABEN 5/2.5 can interact with other medications, so it is important to tell your doctor about all of the medications you are taking.

Patient Counselling

  • Indication: SIXABEN 5/2.5 is indicated for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation.
  • Dosage and administration: The recommended dosage of SIXABEN 5/2.5 is:
    • 5 mg once daily for patients weighing 60 kg or more.
    • 2.5 mg twice daily for patients weighing less than 60 kg.
  • Adverse reactions: The most common side effects of SIXABEN 5/2.5 are:
    • Bleeding
    • Nausea
    • Vomiting
    • Diarrhea
    • Constipation
    • Headache
    • Back pain
    • Fatigue

Warnings and precautions:

  • SIXABEN 5/2.5 can increase the risk of bleeding.
  • SIXABEN 5/2.5 should not be used in patients with liver or kidney problems.
  • SIXABEN 5/2.5 can interact with other medications, so it is important to tell your doctor about all of the medications you are taking.
  • Storage: Store at 25°C (77°F) and below.
  • Disposal: Dispose of unused medication properly.

It is important to emphasize the following points to patients taking SIXABEN 5/2.5:

  • The risk of bleeding is increased with SIXABEN 5/2.5, so it is important to be careful when taking other medications that can also increase the risk of bleeding, such as aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs).
  • If you experience any unusual bleeding, such as bleeding from the gums, nose, or GI tract, you should contact your doctor immediately.
  • If you are taking any other medications, it is important to tell your doctor about them so that they can assess the risk of interactions.
  • SIXABEN 5/2.5 should be stored at room temperature and out of reach of children.
  • Unused medication should be disposed of properly.

About Intra Life

Intra Life is a leading pharmaceutical company that is dedicated to providing high-quality, innovative supplements that can help people live healthier lives. Intra Life is committed to research and development, and it is constantly working to bring new and improved products to market.

Our Mission

Our mission is to improve the lives of patients by providing them with access to affordable, high-quality medications.

Our Vision

We envision a world where everyone has access to the medications they need to live healthy lives.

Our Values

Integrity: We are committed to conducting our business with honesty and transparency.

Excellence: We strive to provide our customers with the highest quality products and services.

Innovation: We are committed to developing new and innovative medications that meet the needs of patients.

INTERESTED IN COLLABORATING WITH US?

CONTACT US